Health & Biotech
Melbourne biotech Mesoblast (ASX:MSB) is attempting to commercialise a stem cell treatment known as remestemcel-L for conditions such as acute graft versus host disease, advanced heart failure and chronic lower back pain due to degenerative disc disease. Mesoblast acquired remestemcel-L from US-based Osiris Therapeutics in 2013.
Mesoblast’s proprietary process selects precursors and stem cells from the bone marrow of healthy adults, creating a master cell bank. This cell bank is then expanded into thousands of doses for off-the-shelf use, without the need for tissue matching.
Mesoblast debuted on the ASX in 2004 and reached a peak valuation of $2.5 billion in 2011. The company dual listed on the Nasdaq in November 2015, accompanied by a $US63m capital raising.
The company was dealt a blow in October 2020 when the US Food and Drug Administration declined to approve remestemcel-L for the treatment of acute graft versus host disease in children, instead asking for more data. Mesoblast is expected to dispute the FDA’s decision.
Mesoblast licensed remestemcel-L to Swiss pharmaceutical giant Novartis in November 2020 for indications other than graft versus host disease, a devastating complication from bone marrow transplants.
RELATED STOCKHEAD STORIES
News
ASX Small Caps and IPO Weekly Wrap: A short week for a small win on the ASX
Health & Biotech
ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX too timid on Tuesday. Although Dart Mining has a decent Mesoblast
News
ASX Small Caps Lunch Wrap: Guess which nation is facing a single-surname crisis this week?
News
ASX Small Caps and IPO Weekly Wrap: Goldies ruled the roost as we got teased by a 10-bagger
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: Tech stocks drag ASX lower; Mesoblast jumps 50pc after all-clear from FDA
Health & Biotech
ASX Health Stocks: Dimerix ACTION3 Phase 3 interim trial results are out… and they’re good
News
Rise and Shine: Everything you need to know before the ASX opens
News
In Case You Missed It: A thing, a different thing and an amusing play on words, I guess
Health & Biotech
ASX Health Stocks: Mesoblast rockets 20pc after being granted Rare Pediatric Disease Designation by FDA
News
Top 10 at 10: FDA wins on a Friday
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
News
ASX Large Caps: Origin shareholders block takeover bid and RBA pauses, as ASX200 takes a 1pc hit
News
Short & Caught: Pilbara Minerals is the ASX’s most shorted as lithium prices tumble
Health & Biotech